Dylst Pieter, Vulto Arnold, Simoens Steven
Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Herestraat 49, O&N 2, P.O. Box 521, 3000 Leuven, Belgium.
Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):795-803. doi: 10.1586/14737167.2014.946011. Epub 2014 Aug 6.
The market share of generic medicines in France is low compared to other European countries. This perspective paper provides an overview of the generic medicines retail market in France and how the current policy environment may affect the long-term sustainability. Looking at the French generic medicines retail market and the surrounding regulatory framework, all conditions seem to be in place to create a healthy generic medicines market: the country has well-respected regulatory authorities, generic medicines enter the market in a timely manner and prices of generic medicines are competitive compared with other European countries. Despite the success of the demand-side policies targeted at pharmacists and patients, those targeted at physicians were less successful due to a lack of enforcement and a lack of trust in generic medicines by French physicians. Recommendations to increase the use of generic medicines in France round off this perspective paper.
与其他欧洲国家相比,法国仿制药的市场份额较低。本观点论文概述了法国仿制药零售市场以及当前的政策环境可能如何影响其长期可持续性。审视法国仿制药零售市场及其周边监管框架,似乎已具备打造健康仿制药市场的所有条件:该国拥有备受尊敬的监管机构,仿制药及时进入市场,且与其他欧洲国家相比,仿制药价格具有竞争力。尽管针对药剂师和患者的需求侧政策取得了成功,但针对医生的政策却不太成功,原因是缺乏执行力度以及法国医生对仿制药缺乏信任。本文最后提出了一些增加法国仿制药使用量的建议。